<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500744</url>
  </required_header>
  <id_info>
    <org_study_id>111510</org_study_id>
    <nct_id>NCT03500744</nct_id>
  </id_info>
  <brief_title>Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery</brief_title>
  <official_title>Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Regional anesthesia, also know as a nerve block, is a key component of pain control after&#xD;
      major abdominal surgery. Bilateral erector spinae plane block (ESPB) performed at low&#xD;
      thoracic level has been shown to be an effective pain control method in case reports. This&#xD;
      pilot study aims to further characterize the pain-control characteristics and to provide&#xD;
      baseline data for future trials.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Sham block will be performed</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>First 12 postoperative hour</time_frame>
    <description>Postoperative opioid consumption in oral morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain score</measure>
    <time_frame>First 12 postoperative hour</time_frame>
    <description>Numeric rating scale (0 - 10) for pain score, area under curve first 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in post-anesthetic recovery unit</measure>
    <time_frame>until discharge from post-anesthetic recovery unit, up to 4 hours postoperaively</time_frame>
    <description>Length of stay in post-anesthetic recovery unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>until discharge from hospital, up to 7 days postoperatively</time_frame>
    <description>Length of stay in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with opioid related complication</measure>
    <time_frame>Until discharge, up to 7 days postoperatively</time_frame>
    <description>Nausea, vomiting, pruritus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with block related complication</measure>
    <time_frame>Until discharge, up to 7 days postoperatively</time_frame>
    <description>Hematoma, nerve deficit, pneumothorax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score 12 - 24 hour</measure>
    <time_frame>12th to 24th postoperative hour</time_frame>
    <description>Area under curve of Numeric rating scale(0 - 10) pain score during the 12 to 24th postoperative hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption 12 - 24 hour</measure>
    <time_frame>12th to 24th postoperative hour</time_frame>
    <description>Postoperative opioid consumption in oral morphine equivalents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hysterectomy</condition>
  <condition>Cystectomy</condition>
  <condition>Regional Anesthesia</condition>
  <arm_group>
    <arm_group_label>Erector spinae plane block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.&#xD;
Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shame block</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.&#xD;
Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector spinae plane block</intervention_name>
    <description>Ropivacaine 0.5% 20 mL at each site of ESPB</description>
    <arm_group_label>Erector spinae plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham block</intervention_name>
    <description>Skin infiltration only</description>
    <arm_group_label>Shame block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult surgical patients who are American Society of Anesthesiologists (ASA) class I to III,&#xD;
        undergoing cystectomy, or total abdominal hysterectomy, salpingo-oophrectomy with or&#xD;
        without omentectomy via midline laparotomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. BMI &gt; 40&#xD;
&#xD;
          2. Non-English speaking&#xD;
&#xD;
          3. Patient refusal or inability to consent&#xD;
&#xD;
          4. Cognitive or psychiatric history that would make it difficult to assess pain score&#xD;
&#xD;
          5. Pre-existing chronic pain condition&#xD;
&#xD;
          6. Preoperative opioid use greater than the equivalent of oral morphine 30 mg daily&#xD;
&#xD;
          7. Infection over site of block placement&#xD;
&#xD;
          8. Allergy or contraindication to any study medication&#xD;
&#xD;
          9. Coagulopathy or thrombocytopenia&#xD;
&#xD;
         10. Postoperative ICU admission&#xD;
&#xD;
         11. Presence of significant cardiac, respiratory, hepatic, renal or neurologic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheng Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Lin, MD</last_name>
    <phone>5196858500</phone>
    <email>cheng.lin@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cheng Lin</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>n6c6a7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheng Lin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Kamal Kumar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

